Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C51H88O60S13 |
Molecular Weight | 2078.053 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]5([H])O[C@H](COS(O)(=O)=O)[C@@H](O[C@@]6([H])O[C@H](COS(O)(=O)=O)[C@@H](O[C@@]7([H])O[C@H](COS(O)(=O)=O)[C@@H](O[C@@]8([H])O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]8OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]7OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]6OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]5OS(O)(=O)=O)[C@H](C)CCCC(C)C
InChI
InChIKey=LNUFLCYMSVYYNW-ZPJMAFJPSA-N
InChI=1S/C51H88O60S13/c1-22(2)7-6-8-23(3)27-11-12-28-26-10-9-24-17-25(13-15-50(24,4)29(26)14-16-51(27,28)5)95-46-42(108-121(79,80)81)38(104-117(67,68)69)34(30(96-46)18-91-112(52,53)54)100-47-43(109-122(82,83)84)39(105-118(70,71)72)35(31(97-47)19-92-113(55,56)57)101-48-44(110-123(85,86)87)40(106-119(73,74)75)36(32(98-48)20-93-114(58,59)60)102-49-45(111-124(88,89)90)41(107-120(76,77)78)37(103-116(64,65)66)33(99-49)21-94-115(61,62)63/h22-49H,6-21H2,1-5H3,(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H,88,89,90)/t23-,24+,25+,26+,27-,28+,29+,30-,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47-,48-,49-,50+,51-/m1/s1
Molecular Formula | C51H88O60S13 |
Molecular Weight | 2078.053 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
PG-545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG-545 also inhibits heparanase, the only endoglycosidase which cleaves HS chains in the ECM. The anti- respiratory syncytial virus (RSV) activity of PG-545 was due to both partial inhibition of the virus attachment to cells and a more profound interference with some post-attachment steps as PG-545 efficiently neutralized infectivity of the cell-adsorbed virus. The anti-RSV activity of PG-545 was reduced when tested in the presence of human nasal secretions. Serial passages of RSV in the presence of increasing concentrations of PG-545 selected for weakly resistant viral variants that comprised the F168S and the P180S amino acid substitutions in the viral G protein. PG-545 has an immunomodulatory properties. PG-545 stimulates innate immune responses against tumours in preclinical cancer models. PG-545 is in phase I clinical trial for the treatment of pancreatic cancer.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. | 2011 Feb 15 |
|
Potent anti-respiratory syncytial virus activity of a cholestanol-sulfated tetrasaccharide conjugate. | 2012 Jan |
|
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. | 2015 Mar 10 |
|
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. | 2015 May |
|
The Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles. | 2016 Feb |
|
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. | 2016 Jan |
|
Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. | 2016 Jan 19 |
|
Heparanase Inhibition Reduces Glucose Levels, Blood Pressure, and Oxidative Stress in Apolipoprotein E Knockout Mice. | 2017 |
|
Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth. | 2017 Aug |
|
The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression. | 2017 Mar |
|
Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545. | 2017 May 23 |
|
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. | 2018 Apr |
|
Prophylactic Antiheparanase Activity by PG545 Is Antiviral In Vitro and Protects against Ross River Virus Disease in Mice. | 2018 Apr |
|
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors. | 2018 Jun 14 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29531325
25, 50, 100 and 150 mg once weekly for 28 days
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:55:42 GMT 2023
by
admin
on
Sat Dec 16 11:55:42 GMT 2023
|
Record UNII |
66QR34C83N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
57412325
Created by
admin on Sat Dec 16 11:55:43 GMT 2023 , Edited by admin on Sat Dec 16 11:55:43 GMT 2023
|
PRIMARY | |||
|
300000034341
Created by
admin on Sat Dec 16 11:55:43 GMT 2023 , Edited by admin on Sat Dec 16 11:55:43 GMT 2023
|
PRIMARY | |||
|
1144617-49-1
Created by
admin on Sat Dec 16 11:55:43 GMT 2023 , Edited by admin on Sat Dec 16 11:55:43 GMT 2023
|
PRIMARY | |||
|
10685
Created by
admin on Sat Dec 16 11:55:43 GMT 2023 , Edited by admin on Sat Dec 16 11:55:43 GMT 2023
|
PRIMARY | |||
|
C95202
Created by
admin on Sat Dec 16 11:55:43 GMT 2023 , Edited by admin on Sat Dec 16 11:55:43 GMT 2023
|
PRIMARY | |||
|
66QR34C83N
Created by
admin on Sat Dec 16 11:55:43 GMT 2023 , Edited by admin on Sat Dec 16 11:55:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|